Akari Therapeutics Management
Management criteria checks 1/4
Akari Therapeutics' CEO is Samir Patel, appointed in May 2024, has a tenure of less than a year. directly owns 10.79% of the company’s shares, worth $2.69M. The average tenure of the management team and the board of directors is 0.8 years and 0.3 years respectively.
Key information
Samir Patel
Chief executive officer
US$9.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 10.8% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Akari Therapeutics GAAP EPS of $0.00
Sep 27Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Sep 20
Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment
Jul 28Akari Therapeutics GAAP EPS of $0.00
Jul 20Patient completes course with Akari's stem cell transplant related complication treatment
Jul 07We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate
Dec 31Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan
Apr 28Akari Therapeutics reports FY results
Apr 21We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
Mar 15Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?
Jan 21Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares
Dec 17Akari Therapeutics updates trial progress; returns to profitability
Dec 11Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease
Dec 03CEO
Samir Patel (55 yo)
less than a year
Tenure
US$9,807
Compensation
Dr. Samir Rashmikant Patel is President of Akari Therapeutics, Plc from 2025 and served as it's Interim President from May 1,2024. Dr. Samir Rashmikant Patel, M.D., serves as Chief Executive Officer at Aka...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$9.81k | 10.79% $ 2.7m | |
| Chief Financial Officer | less than a year | US$331.74k | 0.00081% $ 201.9 | |
| Chief Scientific Officer | no data | no data | no data | |
| Executive Director & Head of Oncology | 2.3yrs | no data | no data |
0.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: AKTX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$9.81k | 10.79% $ 2.7m | |
| Independent Director | less than a year | no data | 2.07% $ 515.5k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0.065% $ 16.2k | |
| Chairman | no data | no data | 15.8% $ 3.9m | |
| Independent Director | 10.1yrs | US$113.00k | 8.31% $ 2.1m | |
| Independent Director | less than a year | no data | 0.19% $ 47.8k |
0.3yrs
Average Tenure
56yo
Average Age
Experienced Board: AKTX's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 23:52 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |